1. Home
  2. CCD vs CRMD Comparison

CCD vs CRMD Comparison

Compare CCD & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Dynamic Convertible & Income Fund

CCD

Calamos Dynamic Convertible & Income Fund

SELL

Current Price

$19.35

Market Cap

662.0M

Sector

Finance

ML Signal

SELL

Logo CorMedix Inc.

CRMD

CorMedix Inc.

HOLD

Current Price

$4.76

Market Cap

590.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCD
CRMD
Founded
2014
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
662.0M
590.7M
IPO Year
2014
2009

Fundamental Metrics

Financial Performance
Metric
CCD
CRMD
Price
$19.35
$4.76
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $13.80
AVG Volume (30 Days)
82.5K
★ 2.0M
Earning Date
01-01-0001
11-12-2026
Dividend Yield
★ 10.61%
N/A
EPS Growth
N/A
★ 780.00
EPS
N/A
★ 0.57
Revenue
N/A
★ $311,709,000.00
Revenue This Year
N/A
$8.05
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$8.45
Revenue Growth
N/A
★ 617.03
52 Week Low
$19.28
$4.72
52 Week High
$26.99
$13.02

Technical Indicators

Market Signals
Indicator
CCD
CRMD
Relative Strength Index (RSI) 28.45 24.97
Support Level N/A N/A
Resistance Level $25.90 $8.79
Average True Range (ATR) 0.65 0.53
MACD -0.08 -0.14
Stochastic Oscillator 0.92 1.10

Price Performance

Historical Comparison
CCD
CRMD

About CCD Calamos Dynamic Convertible & Income Fund

Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.

About CRMD CorMedix Inc.

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Share on Social Networks: